Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

66.70
-0.9800-1.45%
Post-market: 66.41-0.2900-0.43%19:30 EDT
Volume:1.59M
Turnover:106.77M
Market Cap:12.89B
PE:176.00
High:68.34
Open:67.55
Low:66.52
Close:67.68
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.90
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.04
PE(LYR):37.06

Loading ...

U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology

Reuters
·
May 19

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

Simply Wall St.
·
May 19

BioMarin initiated with a Buy at Citi

TIPRANKS
·
May 19

BioMarin Pharmaceutical Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: HealthStream (HSTM) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 18

BUZZ-BioMarin falls after genetic disease therapy shows mixed results in study

Reuters
·
May 18

BioMarin price target lowered to $50 from $55 at H.C. Wainwright

TIPRANKS
·
May 18

Biomarin Pharmaceutical Inc. : H.c. Wainwright Cuts Target Price to $50 From $55

THOMSON REUTERS
·
May 18

BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study

MT Newswires Live
·
May 18

Biomarin Pharmaceutical Shares Down 1% After Genetic Disease Therapy Shows Mixed Results in Late-Stage Study

THOMSON REUTERS
·
May 18

BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial

TIPRANKS
·
May 18

BioMarin's genetic disease therapy shows mixed results in late-stage study

Reuters
·
May 18

Biomarin Pharmaceutical Inc - Energy 3 Study Meets 1 of 2 Co-Primary Endpoints in Enpp1 Deficiency

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Bmn 401 Generally Well-Tolerated With No New Safety Signals Reported

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - No Improvement in Radiagraphic Global Impression of Change Scores in Energy 3 Study

THOMSON REUTERS
·
May 18

Biomarin Provides Update on Phase 3 Trial for Bmn 401 in Children Aged 1-12 With Enpp1 Deficiency

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Bmn 401 Shows Significant Increase in Plasma Inorganic Pyrophosphate in Energy 3 Study

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Evaluating Data to Determine Next Steps for Bmn 401

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - No Positive Trends in Secondary Endpoints Including Rickets Severity Score and Growth Z-Score

THOMSON REUTERS
·
May 18

BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors

TIPRANKS
·
May 15